Tumutolova O.M.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tumutolova O.M. has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Deryabina O.N.
National research Mordovia State University named after N. P. Ogarev
3 shared publications - Ekaterina Valeryevna Blinova
Sechenov University
3 shared publications - Anna A. Epishkina
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
1 shared publication - Anna Epishkina
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)
1 shared publication - Dagar E.A.
N.P. Ogarev Mordovia State University, Saransk, Republic of Mordovia, Russian Federation
1 shared publication Demura T.A.
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
1 shared publication
Latest Publications
- 19 September 2022
- Published by Technomed Holdings LLC in Bulletin "Biomedicine and sociology"
PHARMACOLOGICAL ACTIVITY OF LHT-17-19 IN CULTURES OF EGFR-EXPRESSING EPITHELIAL TUMORS
. In the study, the pharmacological activity of the pyridine derivative LHT-17-19 was studied in relation to the culture of pancreatic cancer cells PANC-1 and the culture of bladder cancer cells HT-29 expressing the epidermal growth factor receptor. The cultures were obtained from the library of tumor strains of the Moscow Research Institute of Oncology. P.A. Herzen - a separate structural subdivision of the Federal State Budgetary Institution "NMITs Radiology" of the Ministry of Health of Russia. LHT-17-19 was synthesized in the Department of Chemistry, Technology of Synthetic Medicines and Analytical Control of JSC VNTs BAV (Russia). LHT-17-19 and the reference drug "Doxorubicin" 50 mg each were added to the cultivation medium in the concentration range from 10-8 to 10-v. Compounds LHT-17-19 were shown to be able to induce death and suppress the growth of pancreatic cancer squamous culture (PANC-1) and bladder (HT-29) tumor cells expressing EGFR over a wide range of concentrations. So for pancreatic cancer (PANC-1), the effective inhibitory concentration for the compound LHT-17-19 was 1.3 × 10-7 M, while for the reference substance doxorubicin it was 6.0 × 10-5 M. bubble (NT-29) - 2.4 × 10-7 M and 5.2 × 10-4 M, respectively.
- 19 September 2022
- Published by Technomed Holdings LLC in Bulletin "Biomedicine and sociology"
PHARMACOLOGICAL ACTIVITY OF LHT-17-19 IN CULTURES OF EGFR-EXPRESSING EPITHELIAL TUMORS
. In the study, the pharmacological activity of the pyridine derivative LHT-17-19 was studied in relation to the culture of pancreatic cancer cells PANC-1 and the culture of bladder cancer cells HT-29 expressing the epidermal growth factor receptor. The cultures were obtained from the library of tumor strains of the Moscow Research Institute of Oncology. P.A. Herzen - a separate structural subdivision of the Federal State Budgetary Institution "NMITs Radiology" of the Ministry of Health of Russia. LHT-17-19 was synthesized in the Department of Chemistry, Technology of Synthetic Medicines and Analytical Control of JSC VNTs BAV (Russia). LHT-17-19 and the reference drug "Doxorubicin" 50 mg each were added to the cultivation medium in the concentration range from 10-8 to 10-v. Compounds LHT-17-19 were shown to be able to induce death and suppress the growth of pancreatic cancer squamous culture (PANC-1) and bladder (HT-29) tumor cells expressing EGFR over a wide range of concentrations. So for pancreatic cancer (PANC-1), the effective inhibitory concentration for the compound LHT-17-19 was 1.3 × 10-7 M, while for the reference substance doxorubicin it was 6.0 × 10-5 M. bubble (NT-29) - 2.4 × 10-7 M and 5.2 × 10-4 M, respectively.
- 30 June 2021
- Published by Technomed Holdings LLC in Bulletin "Biomedicine and sociology"
PHARMACOLOGICAL ACTIVITY OF AN AMINOCHROMENE DERIVATIVE IN THE TREATMENT OF BREAST CANCER (EXPERIMENTAL STUDY)
We studied an antitumor effect of a compound of 4-aminochromene derivatives (AX-554) in the tumor system of breast cancer Ca-755. We used C57Bl / 6 mice, which were subcutaneously injected with a suspension of Ca-755 tumor cells into the right axillary region in the amount of 1×106 cells in 199 solution. AX-554 was administered intragastrically through a tube once on the 48 hours after tumor transplantation, in comparison with reference antitumor drugs with proven antitumor activity, which were used as doxorubicin, paclitaxel. The antitumor activity was judged by the survival rate of animals, the size and morphology of the tumor node. It was shown that the 4-aminochromene derivative AX-554 increases the survival rate of animals with breast cancer by 30% compared with the control group and by 10% with the group receiving doxorubicin. with control. In the study of tumor sections stained with hemotoxylin and eosin in animals treated with AX-554, there were single tumor cells in a state of severe dystrophy, the necrosis zone was 90%, which indicates drug pathomorphosis of the 3rd degree. In animals treated with doxorubicin, atypical cells in the center of the tumor node retained their structure, in the periphery - cells in a state of dystrophy, foci of necrosis accounted for 60%. The morphological picture of the tumor in animals treated with paclitaxel was a drug pathomorphosis of the 2nd degree.
- 30 June 2021
- Published by Technomed Holdings LLC in Bulletin "Biomedicine and sociology"
PHARMACOLOGICAL ACTIVITY OF AN AMINOCHROMENE DERIVATIVE IN THE TREATMENT OF BREAST CANCER (EXPERIMENTAL STUDY)
We studied an antitumor effect of a compound of 4-aminochromene derivatives (AX-554) in the tumor system of breast cancer Ca-755. We used C57Bl / 6 mice, which were subcutaneously injected with a suspension of Ca-755 tumor cells into the right axillary region in the amount of 1×106 cells in 199 solution. AX-554 was administered intragastrically through a tube once on the 48 hours after tumor transplantation, in comparison with reference antitumor drugs with proven antitumor activity, which were used as doxorubicin, paclitaxel. The antitumor activity was judged by the survival rate of animals, the size and morphology of the tumor node. It was shown that the 4-aminochromene derivative AX-554 increases the survival rate of animals with breast cancer by 30% compared with the control group and by 10% with the group receiving doxorubicin. with control. In the study of tumor sections stained with hemotoxylin and eosin in animals treated with AX-554, there were single tumor cells in a state of severe dystrophy, the necrosis zone was 90%, which indicates drug pathomorphosis of the 3rd degree. In animals treated with doxorubicin, atypical cells in the center of the tumor node retained their structure, in the periphery - cells in a state of dystrophy, foci of necrosis accounted for 60%. The morphological picture of the tumor in animals treated with paclitaxel was a drug pathomorphosis of the 2nd degree.
- 30 March 2021
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
EPIDEMIOLOGICAL CHARACTERISTICS OF BREAST CANCER IN THE REPUBLIC OF MORDOVIA
The article analyzes the main epidemiological characteristics of breast cancer in the Republic of Mordovia in comparison with the Russian Federation. Based on the official accounting and reporting documentation for 2011-2019. the territorial and age-specific features of the incidence were determined, the structure of pathomorphological forms of breast cancer was assessed, the weighted average cost of providing specialized medical care for breast neoplasms in a hospital in the Republic of Mordovia was calculated. It has been shown that the incidence of breast cancer in the Republic of Mordovia for 2011-2019 increased, which corresponds to the all-Russian laws: 6.11 per 100 thousand women in the age group of women 25-29 years old to 213.14 in the age group 60-64 years. Infiltrating ductal carcinoma prevailed in the structure of the pathomorphological form of breast cancer among the inhabitants of the Republic - 58.8%. It has been shown that the cost of providing specialized hospital care for stage III breast cancer is 8 times higher than for stages I-II of breast cancer. Thus, the analysis showed that breast cancer is a serious medical and social problem, and effective treatment of the disease requires costly treatment in a specialized hospital, and the cost of drug therapy for the disease increases significantly at advanced stages.
- 30 March 2021
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
EPIDEMIOLOGICAL CHARACTERISTICS OF BREAST CANCER IN THE REPUBLIC OF MORDOVIA
The article analyzes the main epidemiological characteristics of breast cancer in the Republic of Mordovia in comparison with the Russian Federation. Based on the official accounting and reporting documentation for 2011-2019. the territorial and age-specific features of the incidence were determined, the structure of pathomorphological forms of breast cancer was assessed, the weighted average cost of providing specialized medical care for breast neoplasms in a hospital in the Republic of Mordovia was calculated. It has been shown that the incidence of breast cancer in the Republic of Mordovia for 2011-2019 increased, which corresponds to the all-Russian laws: 6.11 per 100 thousand women in the age group of women 25-29 years old to 213.14 in the age group 60-64 years. Infiltrating ductal carcinoma prevailed in the structure of the pathomorphological form of breast cancer among the inhabitants of the Republic - 58.8%. It has been shown that the cost of providing specialized hospital care for stage III breast cancer is 8 times higher than for stages I-II of breast cancer. Thus, the analysis showed that breast cancer is a serious medical and social problem, and effective treatment of the disease requires costly treatment in a specialized hospital, and the cost of drug therapy for the disease increases significantly at advanced stages.
- Open Access
- 30 March 2017
- Published by National Research Mordovia State University MRSU in Mordovia University Bulletin
- Vol. 27 (1)
MONITORING OF HIV-INFECTION IN THE REPUBLIC OF MORDOVIA (UPDATED 2015)
Официальный сайт журнала "Вестник Мордовского университета"
- 30 March 2017
- Published by National Research Mordovia State University MRSU in Mordovia University Bulletin
- Vol. 27 (1)
Open AccessMONITORING OF HIV-INFECTION IN THE REPUBLIC OF MORDOVIA (UPDATED 2015)
Официальный сайт журнала "Вестник Мордовского университета"